IFNB1 and non-small cell lung carcinoma: In a very interesting study by Formenti et al., it was demonstrated that the abscopal response to the combination treatment of RT plus ICIs in patients with non-small-cell lung cancer (NSCLC) was characterized by IFN-β production and induction of systemic antitumor T-cell immunity [78].